Personalized abiraterone or enzalutamide plan for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial compares a personalized (adaptive) treatment plan versus a steady (continuous) plan using either abiraterone or enzalutamide (with the same standard hormone-suppression). It aims to see which approach controls advanced metastatic prostate cancer better while keeping side effects manageable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and can sign consent.
- You have prostate cancer confirmed by biopsy or cell testing, and it has spread to other parts of the body.
- Your testosterone is already kept very low using hormone therapy or surgery, and you’ve been getting worse despite it.
- Your PSA blood level is at least 2, and your cancer symptoms are reasonably controlled.
- You can swallow the study pills and attend required study visits and tests (including sharing tissue or getting a new biopsy).
- You have enough blood counts and healthy enough liver/kidney function for trial treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a new medicine (TVB-2640) combined with enzalutamide in men with prostate cancer that has spread and is no longer responding to hormone treatment. It aims to find a safe dose and see how well the treatment can work against the cancer.
This trial tests a targeted, high-dose radiation therapy (SBRT) plus a newer hormone drug (abiraterone or enzalutamide) for men whose prostate cancer has spread to a small number of spots (5 or fewer) and is no longer controlled by standard hormone therapy.
This trial tests whether a new version of the drug abiraterone (abiraterone acetate II) works as well as the standard version for men with metastatic castration-resistant prostate cancer (MCRPC) that has progressed. You may qualify if you have already had one type of hormone therapy or chemotherapy and your cancer is spreading.
This Phase 2 trial tests whether abiraterone, enzalutamide, or apalutamide can work better (or differently) in men with prostate cancer that is considered “castration-sensitive.” It compares these hormone-blocking treatments to find an approach that controls the cancer more effectively and safely.
This trial tests a new medicine (BMS-986365) against the doctor's choice of standard therapy for men with metastatic castration-resistant prostate cancer. It aims to see which treatment works better and is safer.
This Phase 2 trial tests whether giving testosterone first, then enzalutamide (a prostate cancer hormone-blocking pill), can slow or prevent worsening metastatic prostate cancer. It is designed for men whose cancer progressed despite ongoing hormone-suppression treatment.
Hear when a new Prostatic Neoplasms, Castration-Resistant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.